StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)

Close on Nov 17, 2026Market cap $6.07BP/E –Yield –

Arrowhead Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Arrowhead Pharmaceuticals's total debt was $2.10M at Sep 30, 2018. For fiscal 2018 it was $2.10M, down 9.6% from the year before. The highest annual figure on record is $2.53M in fiscal 2016.

Annual total debt

PeriodPeriod endValueChange
FY2018Sep 30, 2018$2.10M-9.6%
FY2017Sep 30, 2017$2.33M-8.2%
FY2016Sep 30, 2016$2.53M+4966.9%
FY2013Sep 30, 2013$50.00K-94.0%
FY2012Sep 30, 2012$839.42K+38.3%
FY2011Sep 30, 2011$606.79K–

Quarterly total debt

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2018CQ3 2018Sep 30, 2018$2.10M-9.6%
Q3 FY2018CQ2 2018Jun 30, 2018$2.16M-9.2%
Q2 FY2018CQ1 2018Mar 31, 2018$2.22M-8.9%
Q1 FY2018CQ4 2017Dec 31, 2017$2.27M-8.5%
Q4 FY2017CQ3 2017Sep 30, 2017$2.33M-8.2%
Q3 FY2017CQ2 2017Jun 30, 2017$2.38M–
Q2 FY2017CQ1 2017Mar 31, 2017$2.43M–
Q1 FY2017CQ4 2016Dec 31, 2016$2.48M–
Q4 FY2016CQ3 2016Sep 30, 2016$2.53M–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?